CRISPR Therapeutics AG CRSP
$ 46.2
-2.24%
Quarterly report 2024-Q3
added 11-05-2024
CRISPR Therapeutics AG Income Statement 2011-2024 | CRSP
Annual Income Statement CRISPR Therapeutics AG
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
6.5 B | 3.64 B | 5.76 B | 10.1 B | 2.85 B | 1.55 B | 1.67 B | 217 M | - | - | - | - | - |
Shares |
79.2 M | 77.7 M | 75.9 M | 65.9 M | 54.4 M | 48 M | 40.1 M | 12.3 M | - | - | - | - | - |
Historical Prices |
82 | 46.9 | 75.8 | 153 | 60.9 | 28.6 | 23.5 | 20.3 | - | - | - | - | - |
Net Income |
-154 M | -650 M | 378 M | -349 M | 66.9 M | -165 M | -68.4 M | -23.2 M | -25.8 M | -6.8 M | - | - | - |
Revenue |
371 M | 1.2 M | 915 M | 719 K | 290 M | 3.12 M | 41 M | 5.16 M | 247 K | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-223 M | -673 M | 374 M | -354 M | 46.7 M | -159 M | -64.6 M | -68.1 M | -25.7 M | -6.63 M | - | - | - |
Interest Expense |
71.8 M | 22.7 M | 6 M | 6.38 M | 26 M | -1.21 M | -197 K | 78.5 M | 16 K | -236 K | - | - | - |
EBITDA |
-203 M | -649 M | 391 M | -345 M | 51.5 M | -155 M | -61.6 M | -67.2 M | -25.6 M | -6.82 M | - | - | - |
Operating Expenses |
594 M | 674 M | 541 M | 355 M | 243 M | 162 M | 106 M | 73.3 M | 26 M | - | - | - | - |
General and Administrative Expenses |
76.2 M | 102 M | 99.7 M | 85.7 M | 63.5 M | 48.3 M | 35.8 M | 31.1 M | 13.4 M | 5.11 M | - | - | - |
All numbers in USD currency
Quarterly Income Statement CRISPR Therapeutics AG
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
85.2 M | 84.9 M | 81.8 M | 80 M | 79.4 M | 79.1 M | 78.7 M | 78.5 M | 78 M | 77.5 M | 77.1 M | 77 M | 76.3 M | 75.8 M | 75 M | 71.3 M | 70.1 M | 61.4 M | 60.8 M | 57.4 M | 54.8 M | 53.2 M | 52.1 M | 51.7 M | 47.4 M | 46.8 M | 45.9 M | 40.5 M | 40.1 M | 39.9 M | 39.7 M | 33 M | 5.29 M | 5.45 M | 5.53 M | 5.53 M | 5.53 M | 4.54 M | 3.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-85.9 M | -126 M | -117 M | - | -112 M | -77.7 M | -53.1 M | - | -175 M | -186 M | -179 M | - | -127 M | 759 M | -113 M | -107 M | -92.4 M | -79.7 M | -69.7 M | 30.5 M | 138 M | -53.7 M | -48.4 M | -47.6 M | -50.7 M | -38.4 M | -28.3 M | 140 K | -24.7 M | -22.3 M | -21.5 M | 17.1 M | -14.7 M | -17.2 M | -8.44 M | -12.3 M | -6.35 M | -3.64 M | -3.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
602 K | 517 K | 504 K | - | - | 70 M | 100 M | - | 94 K | 158 K | 940 K | - | 824 K | 901 M | 539 K | 370 K | 148 K | 44 K | 157 K | 77 M | 212 M | 318 K | 328 K | 115 K | 563 K | 1.09 M | 1.36 M | 32.3 M | 2.39 M | 3.58 M | 2.7 M | 2.34 M | 1.55 M | 795 K | 476 K | 247 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-110 M | -151 M | -141 M | - | -132 M | -95.2 M | -64.5 M | - | -182 M | -183 M | -176 M | - | -129 M | 763 M | -115 M | -108 M | -92.4 M | -80.7 M | -73.6 M | 11 M | 139 M | -55 M | -48.4 M | -45.2 M | -49.4 M | -37.3 M | -27 M | 972 K | -23.6 M | -21.3 M | -20.7 M | -25.3 M | -14.6 M | -16.6 M | -11.7 M | -12.2 M | -6.2 M | -3.62 M | -3.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
25.1 M | 26.1 M | 24.7 M | - | 20.7 M | 18.4 M | 12.7 M | - | 7.26 M | 3.54 M | 363 K | - | 1.1 M | 750 K | 1.96 M | - | - | - | - | - | 2.96 M | 2.38 M | 1.12 M | - | -130 K | 155 K | -126 K | - | -71 K | -161 K | -6 K | - | -75 K | 80 K | -146 K | - | 9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-105 M | -146 M | -136 M | - | -128 M | -90.2 M | -59.4 M | - | -177 M | -176 M | -170 M | - | -117 M | 769 M | -112 M | -108 M | -85.8 M | -76.4 M | -71.5 M | 11 M | 142 M | -53 M | -47.6 M | -45.2 M | -46.9 M | -35.6 M | -26.2 M | 972 K | -21.4 M | -19.9 M | -20 M | -25.3 M | -14.1 M | -16.3 M | -11.5 M | -12.2 M | -6.13 M | -3.62 M | -3.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
111 M | 152 M | 141 M | - | 132 M | 165 M | 164 M | - | 182 M | 183 M | 177 M | - | 130 M | 138 M | 115 M | 108 M | 92.5 M | 80.7 M | 73.7 M | 66 M | 72.8 M | 55.3 M | 48.8 M | 45.3 M | 50 M | 38.4 M | 28.4 M | 31.4 M | 26 M | 24.9 M | 23.4 M | 27.7 M | 16.2 M | 17.4 M | 12.1 M | 12.4 M | 6.2 M | 3.62 M | 3.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
17.4 M | 19.5 M | 18 M | - | 18.3 M | 19 M | 22.4 M | - | 27 M | 26.3 M | 28 M | - | 23.7 M | 28.8 M | 24.5 M | - | 21.5 M | 21.4 M | 19.6 M | - | 15.5 M | 15.8 M | 14.9 M | - | 10.2 M | 12.7 M | 8.84 M | - | 8.11 M | 7.77 M | 8.64 M | - | 4.11 M | 8.75 M | 6.12 M | - | 2.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency